Tissue factor pathway inhibitor

Drug Profile

Tissue factor pathway inhibitor

Alternative Names: TFPI

Latest Information Update: 26 Jun 2002

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Anticoagulants; Lipoproteins
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Atherosclerosis; Blood coagulation disorders; Reperfusion injury

Most Recent Events

  • 26 Jun 2002 A preclinical study has been added to the Cancer pharmacodynamics section
  • 26 Oct 1999 Two studies have been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics section ,
  • 11 Dec 1997 Preclinical development for Reperfusion injury in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top